关于甲状腺癌靶向药物治疗启动时机的思考  

Thoughts on the timing of targeted therapy initiation for thyroid cancer

作　　者：丁颖[1] 张立 柳宇 邓银倩 陈环宇 兰晓莉[1] 曹卫[1] Ding Ying;Zhang Li;Liu Yu;Deng Yinqian;Chen Huanyu;Lan Xiaoli;Cao Wei(Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Hubei Key Laboratory of Molecular Imaging Key Laboratory of Biological Targeted Therapy of the Ministry of Education,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院核医学科、分子影像湖北省重点实验室、生物靶向治疗教育部重点实验室,武汉430022

出　　处：《中华核医学与分子影像杂志》2023年第8期504-507,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：科技部国家重点研发计划(2017YFC0113302);分子影像湖北省重点实验室开放基金(2020fzyx023)。

摘　　要：近年来靶向药物在持续/复发转移性甲状腺癌及转移性甲状腺髓样癌治疗中的应用取得很大进展,其可显著改善患者的临床症状及预后。然而,靶向治疗药物给患者带来的获益与相关不良事件并存。如何用好靶向药物、增加患者获益并减少不良反应是临床研究的重点。该文讨论靶向药物在晚期甲状腺癌中的应用,思考晚期甲状腺癌靶向药物治疗的启动时机,以期为用好靶向药物提供思路。The treatment of persistent/recurrent and metastatic thyroid cancer and medullary thyroid cancer has made significant progress through the use of molecule-targeted therapy.While this approach has shown promise in improving patient outcomes and clinical symptoms,it also carries potential risks.The primary focus and challenge of targeted therapy is to optimize benefits while managing risks within predetermined thresholds.This review examines current targeted treatment practices in thyroid cancer and investigates the correlation between the timing of targeted therapy initiation and the patient benefits,aiming to lay the groundwork for subsequent research.

关 键 词：甲状腺肿瘤 药物疗法 蛋白激酶抑制剂 发展趋势 

分 类 号：R736.1[医药卫生—肿瘤]